首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.
【24h】

Immunohistochemical analysis of expression of a 65 kDa oncofetal protein (p65), epidermal growth factor receptor (EGFR), oncogene c-erb B2 and tumor suppressor gene p53 protein products in breast cancer patients.

机译:乳腺癌患者中65 kDa癌胚蛋白(p65),表皮生长因子受体(EGFR),癌基因c-erb B2和肿瘤抑制基因p53蛋白产物表达的免疫组织化学分析。

获取原文
获取原文并翻译 | 示例
           

摘要

Paraffin-embedded tissue slides from 88 infiltrating ductal breast carcinoma were examined by immunohistochemistry technique with the use of monoclonal antibody against human p65 antigen and polyclonal antibody against p65-like protein present in fetal bovine serum. Immunohistochemical analysis of expression of growth factor receptors (EGFR), protein product of oncogene c-erb B2 as well as protein product of mutated anti-oncogene p53 was also done. It was established that there is no correlation between p65 and c-erbB2, EGFR or p53 expression. In low differentiated tumors (grade III) high p53 index and high EGFR and c-erbB2 expression was connected with low p65 expression. The lack of c-erbB2 and EGFR and low p53 expression was combined usually with high p65 oncoprotein levels.
机译:通过免疫组织化学技术,使用针对人p65抗原的单克隆抗体和针对胎牛血清中存在的p65样蛋白的多克隆抗体,通过免疫组织化学技术检查了88例浸润性导管癌中石蜡包埋的组织切片。还对生长因子受体(EGFR),癌基因c-erb B2的蛋白质产物以及突变的抗癌基因p53的蛋白质产物进行了免疫组织化学分析。已经确定p65与c-erbB2,EGFR或p53表达之间没有相关性。在低分化肿瘤(III级)中,高p53指数,高EGFR和c-erbB2表达与低p65表达有关。缺乏c-erbB2和EGFR以及低p53表达通常与高p65癌蛋白水平相结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号